Chiara F Magnani

Assistant Professor

University of Zurich

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Chiara F Magnani is an Assistant Professor at the University of Zurich in Switzerland. Her research focuses on innovative approaches to cancer immunotherapy, particularly in the development of CAR T-cell therapies targeting various forms of leukemia and neuroendocrine tumors. Recent publications include work on peptide-guided adaptor-CAR T-cell therapy and genome editing in engineered T cells.

Articles (9)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Alexander Simonis

Center for Molecular Medicine Cologne (CMMC)

GERMANY

View details

CHIARA BURACCHI

ITALY

View details

Antonia Maria Susanne Müller

Department Chair, Professor of Cellular Therapies and Transfusion Medicine

Medical University of Vienna

AUSTRIA

View details

Giovanni Cazzaniga

Associate Professor

University of Milano-Bicocca

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Chiara F Magnani

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells

Genome Editing in Engineered T Cells for Cancer Immunotherapy.

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.

The Past, Present, and Future of Non-Viral CAR T Cells

Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells

Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities.

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.

Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going?

Collaborators (4)

Alexander Simonis

CHIARA BURACCHI

Antonia Maria Susanne Müller

Giovanni Cazzaniga

Make your next move.